Dublin, Sept. 15, 2017 -- The "Drug Discovery Outsourcing Global Market - Forecast to 2025" report has been added to Research and Markets' offering.
Over the last two decades, the Pharmaceutical industry has seen a radical change. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities. As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing.
Almost all the major Pharmaceutical companies are considering outsourcing as a core strategy to fill their discovery pipelines. Outsourcing companies that have precise capabilities through greater flexibility are the preferred ones. Nowadays, the big pharma relies more on CRO's for drug discovery capabilities to stock up their pipelines.
The growth is attributed to the increase in biologics R&D spending and lesser approval time, on the other hand factors such as tedious discovery process and high cost associated are restraining the biologics growth.
The pharmaceutical companies should consider several factors before finalizing a CRO partner like therapeutic area expertise, business model, scientific pool, infrastructure, data security, IP policies and last but not least cost-efficiency. Along with CRO's expertise on drug discovery, the most important aspect the pharma companies look for in a CRO is a verified track record of successfully working in the discovery program of relevant therapeutic area.
Key Topics Covered:
1 Introduction
2 Market Analysis
2.1 Research Methodology
2.2 Forecasting Model
2.3 Market Dynamics
2.4 Market Sizing
2.5 Emerging Trends & Strategies
3 Business Overview
3.1 Business Models
3.2 Business Evolution
3.3 Certifications
3.4 DD Indicators
3.5 Pharma R&D Exp & Intensity
4 Competitor Analysis
4.1 Therapeutic Area Matrix
4.2 Global FTE Rates
4.3 Regional Revenues Vs FTE
4.4 Key players (Revenue Per Employee, Customers, Deals & TA Pie Chart, Collaboration Outcomes)
5 Leading Players
5.1 Overview
5.2 Capabilities
5.3 Therapeutic Area
5.4 Business Models
5.5 Collaborations
5.6 Acquisitions
6 Marketing Strategies
6.1 Conferences
6.2 Match Making Websites
6.3 Virtual Pharmaceuticals
6.4 Online RPFS
6.5 Networking Websites
6.6 Clusters
6.7 Other Marketing Strategies
Companies Mentioned
- Advinus
- AMRI Global
- Aurigene
- Bioduro LLC
- Charles River Laboratories (CRL)
- Chempartner
- Evotec
- GVK Biosciences
- Jubilant Biosys
- Pharmaron Inc.
- Shanghai Medicilon
- Sundia Meditech Co. Ltd.
- Syngene
- TCG Lifesciences
- Wuxiapptec
For more information about this report visit https://www.researchandmarkets.com/research/r7jgns/drug_discovery
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery


Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
First Western Ship Transits Strait of Hormuz Since Iran War Began
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Apple Turns 50: From Garage Startup to AI Crossroads
Britain Courts Anthropic Amid US Defense Department Dispute
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 



